| 13/05/2013
|
Cosmo announces that Shire wins patent trial against Watson concerning LIALDA®
|
| 13/05/2013
|
Cosmo announces placing of Santarus shares successfully completed: Jefferies exercised entire over allotment option
|
| 10/05/2013
|
Cosmo announces placing of 4’250’000 Santarus shares in a secondary stock offering in USA
|
| 10/05/2013
|
Cosmo announces proposed placement of Santarus shares in a secondary stock offering in USA
|
| 28/03/2013
|
Record year for Cosmo in 2012
|
| 01/02/2013
|
The Dutch Regulatory Agency (MEB) reverses decision and approves Cosmo’s Cortiment™ MMX
|
| 25/01/2013
|
2013 R&D Day in Lainate: Cosmo updates investors and analysts on progress and new developments in its R&D pipeline
|
| 15/01/2013
|
Cosmo’s licensee in the US Santarus receives FDA approval of UCERIS™ for the induction of remission in patients with active, mild to moderate ulcerative colitis
|
| 22/10/2012
|
Cosmo announces excellent phase II results for Methylene Blue MMX® in colon cancer diagnosis
|
| 12/09/2012
|
Cosmo announces that its US licensee Santarus reports positive top-line phase III results for rifamycin SV MMX® in travellers’ diarrhoea
|
| 14/08/2012
|
Cosmo’s licensee in the US Santarus announces extension of UCERIS™ application target date to January 16, 2013
|
| 09/08/2012
|
Cosmo receives a communication from the Dutch Regulatory Agency declining approval for Cortiment® MMX
|
| 30/07/2012
|
Cosmo reports very strong increase in revenues and profits in first-half 2012 and substantial progress in development portfolio – confirms outlook
|
| 20/04/2012
|
Cosmo shareholders elect new board and approve increased authority to buy back shares
|
| 02/04/2012
|
Cosmo Licenses Its Anti-Androgen for Certain Topical Applications
|
| 28/03/2012
|
Cosmo reports changes in its board
|
| 23/03/2012
|
Cosmo reports strong 2011 financial and operational results -- Three drugs close to market -- Confident outlook for 2012
|
| 12/03/2012
|
Cosmo announces FDA acceptance of investigational new drug application for CB-03-01
|
| 15/02/2012
|
Cosmo announces FDA acceptance of submission of new drug application for Uceris™ (Budesonide) tablets by its licensee Santarus
|
| 19/01/2012
|
2012 R&D Day: Cosmo updates investors and analysts on progress and new developments in its R&D pipeline in Lainate
|
| 21/12/2011
|
Cosmo announces FDA submission of new drug Application for uceris™ (budesonide) tablets by its Licensee santarus
|
| 20/09/2011
|
Cosmo announces supportive Top-Line results from Budesonide MMX Extended use study
|
| 29/07/2011
|
Cosmo reports strong increase in revenues and profits in first-half 2011 and substantial progress in development portfolio
|
| 19/07/2011
|
Cosmo announces the additional approval of LIALDA in the U.S. for the maintenance of remission in patients with ulcerative colitis
|
| 20/06/2011
|
Cosmo announces very positive results of the first parts of the phase II clinical trials following the live transmission of Blu-Colonoscopy at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano
|
| 16/06/2011
|
Cosmo announces live transmission of Blu-Colonoscopy at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano
|
| 31/05/2011
|
Cosmo announces filing of Budesonide MMX® for treatment of mild to moderate active Ulcerative Colitis in Europe
|
| 25/03/2011
|
Cosmo reports good 2010 operational results
|
| 01/12/2010
|
2010 R&D Day: COSMO updates investors and analysts on progress and new developments in its R&D pipeline
|
| 08/11/2010
|
COSMO ANNOUNCES POSITIVE TOP-LINE RESULTS IN EU PHASE III CLINICAL STUDY EVALUATING BUDESONIDE MMX IN ULCERATIVE COLITIS
|
| 06/10/2010
|
Cosmo reports exciting results in P.O.C. alopecia study
|
| 30/09/2010
|
Cosmo and Santarus announce positive results in U.S. Phase III clinical study evaluating Budesonide MMX® in ulcerative colitis
|
| 30/07/2010
|
Cosmo reports increased revenues and operating profit in first-half 2010
|
| 12/07/2010
|
Shire Files Suit against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc
|
| 31/05/2010
|
Shire receives LIALDA® Paragraph IV Notice Letter from Zydus Pharmaceuticals
|
| 16/04/2010
|
Cosmo Pharmaceuticals announces drop in book value of shares of Santarus
|
| 30/03/2010
|
Ordinary and extraordinary assembly at BioXell
|
| 19/03/2010
|
Cosmo reports good 2009 results
|
| 01/03/2010
|
Cosmo Pharmaceuticals announces preliminary end result of its tender offer for BioXell
|
| 09/02/2010
|
Cosmo Pharmaceuticals announces preliminary interim result of its tender offer for BioXell
|
| 11/12/2009
|
Cosmo’s CB-03-01 phase II pilot study in acne demonstrates superiority over Retin A®
|
| 08/12/2009
|
Cosmo Pharmaceuticals publishes Public Tender Offer for BioXell
|
| 03/12/2009
|
Cosmo Pharmaceuticals reports completion of enrolment in Phase III EU study of Budesonide MMX® for Ulcerative Colitis
|
| 18/11/2009
|
Cosmo Pharmaceuticals offers to acquire BioXell
|
| 30/07/2009
|
Cosmo reports a strong first half-year 2009
|
| 23/03/2009
|
Cosmo reports strong revenue growth, €9.4 million net profit for 2008 and a confident outlook for 2009
|
| 15/12/2008
|
COSMO ANNOUNCES STRATEGIC COLLABORATION WITH SANTARUS FOR U.S. RIGHTS TO BUDESONIDE MMX® AND RIFAMYCIN SV MMX®
|
| 24/11/2008
|
Cosmo announces Licensing Agreement with Dr. Falk Pharma for Rifamycin SV MMX®
|
| 02/09/2008
|
Cosmo successfully completes the first phase I clinical trial of its anti-androgen, CB-03-01, for the treatment of skin disorder
|
| 04/08/2008
|
Cosmo Pharmaceuticals awarded US patent for use of its MMX™ technology
|
| 29/07/2008
|
Cosmo Pharmaceuticals reports HY results
|
| 21/04/2008
|
Cosmo Pharmaceuticals reports highly positive results from the LMW Heparin MMX™ phase IIb trial for Ulcerative Colitis
|
| 01/04/2008
|
Cosmo initiates phase I trials of CB-03-01
|
| 04/03/2008
|
Cosmo announces full year results 2007
|
| 29/11/2007
|
Cosmo’s Rifamycin SV MMX™ meets clinical endpoints in Phase II trial for infectious diarrhoea
|
| 20/11/2007
|
MEZAVANT XL™ launched in the UK
|
| 11/10/2007
|
Cosmo announces Licensing Agreement with Ferring for Budesonide MMX™
|
| 05/10/2007
|
Digestive & Liver Disease journal published an article on Low Molecular Weight Heparin MMX
|
| 05/10/2007
|
Market Making Agreement
|
| 25/07/2007
|
Cosmo Pharmaceuticals reports HY results
|
| 04/07/2007
|
Cosmo Pharmaceuticals reports positive preliminary Phase II/III data with Rifamycin MMX™ in Infectious Diarrhoea
|
| 21/06/2007
|
Disclosure of shareholdings
|
| 06/06/2007
|
Cosmo improves Licensing Agreement with Giuliani for LIALDA™ MMX™
|
| 20/03/2007
|
Cosmo Pharmaceuticals: Market Launch of LIALDA
|
| 15/03/2007
|
Cosmo Pharmaceuticals S.p.A. IPO over-allotment option fully exercised
|
| 08/03/2007
|
Offer price for Cosmo Pharmaceuticals S.p.A.
|
| 26/02/2007
|
Cosmo Pharmaceuticals S.p.A. launches IPO on the SWX Swiss Exchange
|
| 12/02/2007
|
Cosmo Pharmaceuticals S.p.A. seeks a listing on the SWX Swiss Exchange
|
| 17/01/2007
|
LIALDA TM MMX treatment for ulcerative colitis gets FDA approval
|
| 22/12/2006
|
Rolf Stahel appointed non-executive Chairman of Cosmo Pharmaceuticals
|
| 19/12/2006
|
MEZAVANTTM MMX treatment for ulcerative colitis gets label agreement for Europe
|